Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 6/20 | 0.47 |
| ▸ | CCND1 | P24385 | 6/20 | 0.47 |
| ▸ | PRKACA | P17612 | 3/20 | 0.46 |
| ▸ | PRKACG | P22612 | 3/20 | 0.46 |
| ▸ | PRKACB | P22694 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 7/20 | 0.43 |
| ▸ | GSK3A | P49840 | 6/20 | 0.39 |
| ▸ | OPA1 | O60313 | 1/20 | 0.38 |
| ▸ | EIF5B | O60841 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334227 | 0.89 | CDK4 (0.50) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6328643 | 0.82 | CAMK2D (0.49) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6328457 | 0.81 | CDK4 (0.46) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327674 | 0.80 | CDK4 (0.50) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL10150344 | 0.80 | CDK4 (0.50) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327449 | 0.79 | CDK4 (0.59) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6332262 | 0.79 | CDK4 (0.68) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6327465 | 0.79 | CDK4 (0.56) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL6326531 | 0.79 | CDK4 (0.56) | CDK4CCND1PRKACAPRKACGPRKACB | |
| SCHEMBL224940 | 0.78 | CDK4 (0.61) | CDK4CCND1PRKACAPRKACGPRKACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | CDK4 5/4885CCND1 70/4885PRKACA 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.